1. Давыдов М.И., Полоцкий Б.Е. Рак легкого. М.: Радикс, 1994. 206 с.

2. Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: Гэотар-медиа, 2000. 600 с.

3. The health consequences of smoking: a report of the Surgeon General. Available at: https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/consequences-smoking-factsheet/index.html.

4. Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2018. Доступно по: http://www.oncology.ru/service/statistics/condition/2017.pdf

5. Stahel R., Peters S., Garassino M. Thoracic tumours essentials for clinicians. ESMO Press, 2014.

6. WHO classification of tumours of the lung, pleura, thymus and heart 2015.

7. The AJCC Cancer staging manual. Eight ed. Springer, 2017.

8. NCCN Guidelines. Non-small cell lung cancer, version 7.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

9. Grunnet M., Sorensen J.B., Carcinoembrionic antigen (CEA) as a tumor marker in lung cancer. Lung Cancer 2012; 76: 138 - 43.

10. Planchard D., Popat S, Kerr R et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann of Oncology 29 (Supplement 4):192 - 234, 2018

11. Travis D.W., Brambilla E., Burke A.P. et al. Classification of tumours of the lung, pleura, thymus and heart. 4^th ed. Lyon: IARC Press, 2015.

12. Lung cancer. Ed. by F.V. Fossella, J.B. Putnam, R. Komaki. M.D. NewYork: Springer, 2003. 316 p.

13. Schrump D.S., Carter D., Kelsey C.R. et al. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg cancer; prinsiples and practice of oncology. Ed. by V.T. DeVita Jr, T.S. Lawrence, S.A. Rosenberg et al. Philadelphia: Lippincott Williams and Wilkins, 2011.

14. Трахтенберг А.Х., Чиссов В.И., Франк Г.А. Нейроэндокринные опухоли легких. М.: Практическая медицина, 2012. 200 с.

15. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого T1-2N0M0. Вопросы онкологии 2015; 61(3): 413 - 7.

16. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer. J Cardiothorac Surg 2014; 9: 88 - 92.

17. Lindberg K., Nyman J., Riesenfeld Kallskog V. et al. Long-term of a results of prospective trial phase II of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. Acta Oncol 2015; 54: 1096 - 104.

18. Zhang T, Guo Q, Zhang Y, Liu Z, Zhou S, Xu S. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. J Can Res Ther 2018; 14: 139 - 44

19. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatinvs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589 - 97.

20. Arriagada R1, Dunant A, Pignon JPLong-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1; 28(1): 35 - 42. doi: 10.1200/JCO.2009.23.2272.

21. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375(9722): 1267 - 77.

22. Aureperin A., Le Pechoux C., Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 2181 - 90.

23. Tsitsias T., Boulemden A., Ang K. et al. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. J Eur Cardiothorac Surg 2014; 45: 882 - 7.

24. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30: 172 - 8.

25. Strauss G.M., Herndon III J.E., Maddaus M.A. et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043 - 51.

26. Usami N., Yokoi K., Hasegawa Y. et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol 2010; 15: 583 - 7.

27. Fossella F., Pereira J.R., von Pawel J. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016 - 24.

28. M., Chouaid C., D. et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3516 - 24.

29. Kreuter M., Vansteenkiste J., Fishcer J.R. et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol 2013; 24: 986 - 92.

30. Curran W.J., Paulus R., Langer C.J. et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452 - 60.

31. Pignon J.P., Tribodet H., Scagliotti G.V. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552 - 9.

32. Albain KS1, Crowley JJ, Turrisi AT 3rd et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15; 20(16): 3454 - 60.

33. Choy H., Gerber D.E., Bradley J.D. et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer 2015; 87: 232 - 40.

34. Senan S., Brade A., Wang L.H. et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016; 34: 953 - 62.

35. Albain K.S., Crowley J.J., Turrisi A.T. III et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol 2002; 20: 3454 - 60.

36. Bradley J.D., Paulus R., Komaki R. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187 - 99.

37. Antonia S.J., Villegas A., Daniel D. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20): 1919 - 29.

38. Masters G.A., Temin S., Azzoli C.G. et al. Systemic therapy for stage IV non-small cell lung cancer. American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015; 33: 3488 - 515.

39. Kerr K.M., Bubendorf L., Edelman M.J. et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681 - 90.

40. Klastersky J., Sculier J.P., Lacroix H. et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556 - 62.

41. Frasci G., Comella P., Panza N. et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer 1998; 34: 1710 - 4.

42. Ohe Y., Ohashi Y., Kubota K. et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317 - 23.

43. Sandler A., Gray R., Perry M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542 - 50.

44. Scagliotti G.V., Parikh P., von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008; 26: 3543 - 51.

45. Danson S., Middleton M.R., O'Byrne K.J. et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and ciplatin in patients with advanced non-small cell lung carcinoma. Cancer 2003; 98: 542 - 53.

46. Barlesi F., Scherpereel A., Rittmeywr A. et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. J Clin Oncol 2013; 31: 3004 - 11.

47. Zatloukal P., Kanitz E., Magyar P. et al Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer 1998; 22: 243 - 50.

48. Sederholm C., Hillerdal G., Lamberg K. et al. Phase III trial of gemcitabine plus carboplatin versus single agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study group. J Clin Oncol 2005; 23: 8380 - 88.

49. Perol M., Chouaid C., Perol D. et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small celll lung cancer. J Clin Oncol 2012; 30: 3516 - 24.

50. Fossella F.V., DeVore R., Kerr R.N. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354 - 62.

51. Fidias P.M., Dakhil S.R., Lyss A.P. et al. Phase III study of immmediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009; 27: 591 - 8.

52. Hanna N.H., Sheperd F.A., Fossella F.V. et al. Randomized phase III study of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589 - 97.

53. Reck M., Rodriguez-Abreu D., Robinson A.G. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823 - 33.

54. Langer C.J., Gadgeel S.M., Borghaei H. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17(11): 1497 - 508.

55. Lopes G., Wu Y.-L., Kudaba I. et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score >= 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018; 36(18 Suppl).

56. Socinski M.A., Jotte R.M., Cappuzzo F. et al. Atezolizumab in first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288 - 301.

57. Inoue A., Kobayashi K., Usui K. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394 - 400.

58. Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239 - 46.

59. Yang J.C., Wu Y.I., Shuler M. et al. Afatinib versus cisplatin-based chemotherapy for EGFR-mutation-positive lung adenocarcinoma LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol 2015; 16: 141 - 51.

60. Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113 - 25.

61. Solomon B.J., Mok T., Kim D.W. et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2013; 371: 2167 - 77.

62. Soria J.C., Tan D.S.W., Chiari R. et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND 4): a randomized, open-label, phase 3 study. Lancet 2017; 389: 917 - 29.

63. Camidge D.R. Updated efficacy and safety data from the global phase III ALEX global study of alectinib (ALC) versus crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol 2018; 35(Suppl): 9064.

64. Planchard D., Smit E.F., Groen H.J.M. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017; 18: 1307 - 16.

65. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899 - 909.

66. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617 - 25.

67. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010; (5): CD007309.

68. Azzolic G., Temin S., Aliff T. et al. 2011 Focused Update of 2009 American Society of Clinical Oncology clinical practice guideline update of chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825 - 31.

69. D'Addario G., Pintile M., Leighi N.B. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature. J Clin Oncol 2005; 23: 2926 - 36.

70. Zukin M., Barrios C.H., Pereira J.R. et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31: 2849 - 53.

71. Sandler A., Yi J., Dahlberg S. et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacisumab with paclitaxel/carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol 2010; 5: 1416 - 23.

72. Gridelli C., Perrone F., Gallo C. et al. Chemotherapy in elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362 - 72.

73. Corre R., Greillier L., Le Caer H. et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced nonsmall-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 2016; 34: 1476 - 83.

74. Henry H.D., Costa I., Goldwasser F. et al. Randomised, double-blind study of denosumab versus zoledronic acid in the treatment skeletal metastases in patients with advanced cancer (excluded breast and prostate cancer) or multiple myeloma. J ClinOncol 2011; 29: 1125 - 32.

75. Rosen L.S., Gordon D., Tchekmedyian N.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613 - 21.

76. Chow E., Zeng L., Salvo N. et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012; 24: 112 - 24.

77. Gandhi I., Rodriguez-Abreu D., Gadgeel S. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078 - 92.

78. Paz-Ares L., Luft A., Vicente D. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379(21): 2040 - 51.

79. Sheperd F.A., Dancey J., Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095 - 103.

80. Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123 - 35.

81. Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627 - 39.

82. Rittmeyer A., Barlesi F., Waterkamp D. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255 - 65.

83. Herbst R., Garon E., Kim D.-W. et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thoracic Oncol 2017; 12: S254 - 5.

84. Herbst R.S., Baas P., Kim D.W. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540 - 50.

85. Novello S., Kaiser R., Mellengaard A. et al. Analysis of patient-reported outcomes from the LUME-Lung I trial: a randomized, double-blind, placebo-controlled. Phase III study of second line nintedanib in patients non-small-cell lung cancer. Eur J Cancer 2015; 51: 317 - 26.

86. Sculier J.P., Lafitte J.J., Berghmans T. et. al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. The European Lung Cancer Working Party. Lung Cancer 2000; 29: 67 - 73.

87. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T. et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123 - 32.

88. Ciuleanu T., Stelmakh L., Cicenas S. et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13: 300 - 8.

89. Karampeazis A., Voutsina A., Souglakos J. et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013; 119: 2754 - 64.

90. Soria J.C., Felip E., Cobo M. et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015; 16: 897 - 907.

91. Planchard D., Popat S., Kerr K. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv192 - 237.

92. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228 - 47.

93. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207 - 14.

94. Burroto M., Manasanch E.E., Wilkerson J., Fojo T. Gefitinib and erlotinib in metastatic non-small-cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400 - 10.

95. Sequst L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327 - 34.

96. Cross D.A., Ashton S.E., Ghiorghiu S. et al. AZD9291 irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046 - 61.

97. Cho B.C., Kim D.W., Bearz A. et al. ASCEND-8 - a randomized phase I study ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK) rearranged metastatic non-small-cell lung cancer (NSCLC). J Thorac Oncol 2017; 12: 1357 - 67.

98. Shaw A.T., Yeap B.Y., Solomon B.J. et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. J Clin. Oncol 2011; 29(Suppl 15): 7507.

99. Yang B., Lee H., Um S.W. et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer 2019; 129: 28 - 34.

100. Patchell R.A., Tibbs P.A., Walsh J.W. et al. A randomized trial of surgery in the treatment of single metastases to the brain. New Engl J Med 1990; 322: 494 - 500.

101. Noordijk E.M., Vecht C.J., Haaxma-Reiche H. et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994; 29: 711 - 7.

102. Sahgal A., Aoyama H., Kocher M. et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data of meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91: 710 - 7.

103. Priestman T.J., Dunn J., Brada M. et al. Final results of the Royal College of Radiologists' Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 1996; 8: 308 - 15.

104. Batchelor T., DeAngelis L.M. Medical management of cerebral metastases. Neurosurg Clin North Am 1996; 7: 435 - 46.

105. Vecht C.J., Hovestadt A., Verbiest H.B. et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44: 675 - 80.

106. Naruke T. Lymph node metastasis of lung cancer and associated surgery. Asian Med J 1990; 33(12): 668 - 77.

107. Paul S., Altorki N.K., Sheng S. et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database. J Thorac Cardiovasc Surg 2010; 139: 366 - 78.

108. Scott W.J., Allen M.S., Darling G. et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial. J Thorac Cardiovasc Surg 2010; 139: 976 - 81.

109. Ginsberg R.J., Rubinstein L.V. Randomised trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995; 60: 615 - 22.

110. Schreiber D., Rineer J., Weedon J. et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010; 116(5): 1350 - 7.

111. Мелкоклеточный рак легкого. Под ред. М.Б. Бычкова. М., 2013.

112. Bloom B.C., Augustyn A., Sepesi B. et al. Prophylactic cranial irradiation following surgical resection of early-stage small-cell lung cancer: a review of the literature. Front Oncol 2017; 7: 228.

113. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J. et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006; 17: 543 - 52.

114. Turrisi A.T., Kim K., Blum R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265 - 71.

115. Zatloukal P., Cardenal F., Szczesna A. et al A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Ann Oncol 2010; 21(9): 1810 - 6.

116. Rossi A., Di Maio M Chiodini Pet al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30(14): 1692 - 8.

117. Horn L., Mansfeld A.S., Szcz sna A. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220 - 9.

118. Slotman B.J., van Tinteren H., Praag J.O. et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385: 36 - 42.

119. Von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17(2): 658 - 67.

120. Morise M., Niho S., Umemura S., Matsumoto S., Yoh K. et al. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Jpn J Clin Oncol. 2014 Sep; 44(9): 846 - 51. doi: 10.1093/jjco/hyu094. Epub 2014 Jul 23.

121. Antonia S.J., Lopez-Martin J.A., Bendell J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17(7): 883 - 95.

122. Slotman B., Faivre-Finn C., Kramer G. et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357(7): 664 - 72.

123. Van Der Linden Y.M., Van Kempen M.L., Van Der Tweel I. et al. Prophylactic cranial irradiation in limited disease small-cell lung cancer in complete remission: a retrospective analysis. Respir Med 2001; 95(3): 235 - 6.

124. Kepka L., Cieslak E., Bujko K., Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol 2005; 44: 389 - 98.

125. Sommer M.S., Trier K., Vibe-Petersen J. et al. Perioperative rehabilitation in operation for lung cancer (PROLUCA) - rationale and design. BMC Cancer 2014; 14: 404.

126. Sebio R., M.I., E. et al. Impact of a pre-operative pulmonary rehabilitation program on functional performance in patients undergoing video-assisted thoracic surgery for lung cancer. Arch Bronconeumol 2016; 52(5): 231 - 2.

127. Sebio Garcia R., Brage M.I., Moolhuyzen E. et al. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2016; 23(3): 486 - 97.

128. Barassi G., Bellomo R.G., Di Iulio A. et al. Preoperative rehabilitation in lung cancer patients: yoga approach. Adv Exp Med Biol 2018; 1096: 19 - 29.

129. Rogers LJ, Bleetman D, Messenger DE, Joshi NA, et al. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. J Thorac Cardiovasc Surg. 2018; 155(4): 1843 - 1852.

130. Li S, Zhou K, Che G, Yang M, Su J, Shen C1, Yu P. Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res. 2017 Nov 16; 9: 657 - 670. doi: 10.2147/CMAR.S150500.

131. Deng G.E., Rausch S.M., Jones L.W. et. al. complementary therapies and integrative medicine in lung cancer. diagnosis and management of lung cancer, 3^rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143(5 Suppl): e420S-36S.

132. Imperatori A., Grande A., Castiglioni M. et al. Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Interact Cardiovasc Thorac Surg 2016; 23: 223 - 30.

133. Park H., Park J., Woo S.Y. et al. Effect of high-frequency chest wall oscillation on pulmonary function after pulmonary lobectomy for non-small cell lung cancer. Crit Care Med 2012; 40(9): 2583 - 9.

134. Dhillon H.M., van der Ploeg H.P., Bell M.L. et al. The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer 2012; 12: 572.

135. Sun V., Raz D.J., Ruel N. et al. A multimedia self-management intervention to prepare cancer patients and family caregivers for lung surgery and postoperative recovery. Clin Lung Cancer 2017; 18(3): e151-9.

136. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409 - 26.

137. Batty G.D., Russ T.C., Stamatakis E., Kivim ki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ 2017; 356: j108.

138. Luszczynska A., I., Cieslak R. et al. Social support and quality of life among lung cancer patients: a systematic review. Psychooncology 2013; 22(10): 2160 - 8.

139. Li M., Kennedy E., Byrne N. et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psycho-Oncology. 2017; 26: 573 - 87.

140. Janssen S.M., Abbink J.J., Lindeboom R., Vliet Vlieland T.P. Outcomes of pulmonary rehabilitation after treatment for non-small cell lung cancer stages I to IIIa: an observational study. J Cardiopulm Rehabil Prev 2017; 37(1): 65 - 71.

141. Rivas-Perez H., Nana-Sinkam P. et al. Integrating pulmonary rehabilitation into the multidisciplinary management of lung cancer: a review. Respir Med 2015; 109(4): 437 - 42.

142. Andrea L., Kollasch J., Vandenberg J. et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013; 45: 811 - 21.

143. Hilliard R.E. Music therapy in hospice and palliative care: a review of the empirical data. Evid Based Complement Alternat Med 2005; 2(2): 173 - 8.

144. Chen H.Y., Li S.G., Cho W.C.S., Zhang Z.J. The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis. BMC Complement Altern Med 2013; 13: 362.

145. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 304.

146. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26: 1019 - 28.

147. Muzi J.L., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15 Suppl): 9019.

148. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016; 38(2): 85 - 94.

149. M., A., S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014; 46(5): 454 - 60.

150. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

151. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226 - 33.

152. Hetkamp M., Bender J., Rheindorf N. et al. A Systematic Review of the Effect of Neurofeedback in Cancer Patients. Integr Cancer Ther. 2019; 18:1534735419832361. doi:10.1177/1534735419832361

153. Bade B.C., Thomas D.D., Scott J.B., Silvestri G.A. Increasing physical activity and exercise in lung cancer. reviewing safety, benefits, and application. J Thorac Oncol 2015; 10(6): 861 - 71.

154. Williams S., Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006; 94: 372 - 390

155. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

156. LBA5_PR' Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis' will be presented by Suresh S. Ramalingam during the Presidential Symposium I on Saturday, 28 September, 16:30 to 18:20 (CEST) in Barcelona Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019

157. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649 - 655

158. Hendriks L. E. L. et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review//Journal of Thoracic Oncology. - 2016. - Т. 11. - N. 2. - С. 155 - 173.

159. J Clin Oncol. 1999 Jan; 17(1): 12 - 8. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. Cardenal F1, MP, A, Zhao X. et al.

160. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors//Annals of Oncology. - 2017. - Т. 28. - N. 8. - С. 2002 - 2008.

161. Long G. V. et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer//Annals of Oncology. - 2018. - Т. 29. - N. 11. - С. 2208 - 2213.

162. Garon E et al. P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: IT/JTO January 2017 Volume 12, Issue 1, Supplement, Pages S1290 - S1291 DOI: https://doi.org/10.1016/j.jtho.2016.11.1825

163. Morrissey K.M. et al Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing

164. Garassino M. C. et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial//The lancet oncology. - 2013. - Т. 14. - N. 10. - С. 981 - 988.

165. Ahn M. J. et al. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR//The oncologist. - 2014. - Т. 19. - N. 7. - С. 702 - 703.

166. Cho BC, Kim DW, Bearz A ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017 Sep; 12(9): 1357 - 1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17

167. Riely GJ1, Yu EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. HA2Clin Cancer Res. 2015 May 15; 21(10): 2221 - 6. doi: 10.1158/1078-0432.CCR-14-3154.

168. Oxnard GR1, Thress KS2, Alden RS. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer J Clin Oncol. 2016 Oct 1; 34(28): 3375 - 82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.

169. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged nonsmall-cell lung cancer. N Engl J Med 2014; 371: 1963 - 1971.

170. Moro-Sibilot D, Faivre L, Zalcman G et al. Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSE phase II trial. J Clin Oncol 2015; 33: 8065.

171. Mazieres J, Zalcman G, Crino L et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015; 33: 992 - 999. 170

172. Pan J. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report//Clinical Drug Investigation. - 2019. - С. 1 - 5.

173. Planchard D, Smit EF, Groen HJM et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017; 18: 1307 - 1316

174. Planchard D, Besse B, Groen HJM et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic nonsmall cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016; 17: 984 - 993.

175. Planchard D, Smit EF, Groen HJM et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D trametinib (T) in the phase II BRF113928 study. J Clin Oncol 2017; 28(Suppl 5): 9075.

176. Butts CA Ding K, Seymour L et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29 - 34].

177. Burdett S. et al. Postoperative radiotherapy for non small cell lung cancer//Cochrane database of systematic reviews. - 2016. - N. 10.

178. Gilligan D. et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review//The Lancet. - 2007. - Т. 369. - N. 9577. - С. 1929 - 1937.

179. Gridelli C., Chen T., Ko A. et al. Nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial//Drug Des Devel Ther. 2018; 12: 1445 - 1451. Published online 2018 May 24. doi: 10.2147/DDDT.S155750

180. Takagi Y., Hosomi Y., Sunami K. et al. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin-Pemetrexed Therapy for Non-Small Cell Lung Cancer//Oncologist. 2014 Nov; 19(11): 1194 - 1199. Published online 2014 Sep 26. doi: 10.1634/theoncologist.2014-0221

181. Переводчикова Н.И., В.А. Горбунова Руководство по химиотерапии опухолевых заболеваний//Практическая медицина. 2015. - 688 с.

182. Reck M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer//New England Journal of Medicine. - 2016. - Т. 375. - N. 19. - С. 1823 - 1833.

183. Yamamoto N., Tsurutani J., Yoshimura N. et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.//Anticancer Res. 2006 Jan-Feb; 26(1B): 777 - 81.

184. Smit E., Fokkema E., Biesma B., Groen H., Snoek W., Postmus P. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.//Br J Cancer. 1998; 77(2): 347 - 51.

185. Arriagada R., Bergman B., Dunant A. et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer//New England Journal of Medicine. - 2004. - Т. 350. - N. 4. - С. 351 - 360.

186. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191 - 205